Dr.ย Chang-Kiย Min
MD, PhD
Professor of Hematology & Vice-Chancellor, Catholic University Medical Center
corporate_fareSeoul St. Mary's Hospital, Seoul
Chang-Ki Min
MD, PhD
Prof. Chang-Ki Min is a leading haematologist at Seoul St. Mary's Hospital, The Catholic University of Korea, with deep expertise in multiple myeloma, plasma cell disorders, and haematopoietic stem cell transplantation. He currently serves as Professor of Hematology and, from September 2025, as Vice-Chancellor and Medical Director of the Catholic University Medical Center.
With over 35 years in clinical haematology, Prof. Min has built his career at one of South Korea's most prominent haematology and transplant centres. Seoul St. Mary's Hospital became the first institution in Korea to record 10,000 accumulated haematopoietic stem cell transplants, with Prof. Min performing the landmark 10,000th procedure in December 2022. His clinical work covers autologous stem cell transplantation, CAR-T cell therapy, bispecific antibody therapy, targeted immunotherapy, and personalised risk-based treatment planning for myeloma. A 12-year institutional analysis of 1,291 multiple myeloma patients at his centre reported a median overall survival of 80.5 months, reflecting the programme's multidisciplinary approach and structured post-treatment monitoring. He trained at the University of Michigan bone marrow transplant laboratory in 2002, and received the inaugural Leading Researcher Award from the Korean Society for Haematopoietic Stem Cell Transplantation in 2019.
CancerFax can coordinate medical-report review, case preparation, and consultation support for international patients seeking an opinion from Prof. Min at Seoul St. Mary's Hospital.
Why Consider Prof. Chang-Ki Min?
Prof. Min combines 35+ years of focused haematology expertise with leadership of one of Korea's largest transplant programmes, making him a highly sought specialist for multiple myeloma and stem cell transplantation.
Areas of Specialisation
Advanced haematology with a focus on myeloma and stem cell transplantation
Prof. Min's clinical practice centres on multiple myeloma and plasma cell disorders, haematopoietic stem cell transplantation, and cellular therapies including CAR-T. His work spans diagnosis, treatment planning, transplant coordination, and post-treatment monitoring.
Multiple Myeloma & Plasma Cell Disorders
Comprehensive diagnostic and treatment management for newly diagnosed and relapsed/refractory multiple myeloma.
- arrow_rightPersonalised risk-based treatment planning based on cytogenetics and molecular profile
- arrow_rightInduction therapy regimens followed by autologous stem cell transplantation where indicated
- arrow_rightMaintenance therapy and structured post-treatment monitoring
- arrow_rightSecond-line and beyond treatment using novel agents including carfilzomib, pomalidomide, and daratumumab
- arrow_rightBispecific antibody therapy including teclistamab for triple-class exposed patients
- arrow_rightCirculating tumour DNA monitoring for treatment response assessment
Haematopoietic Stem Cell Transplantation
One of Korea's most experienced transplant programmes, now surpassing 10,000 accumulated procedures.
- arrow_rightAutologous SCT as consolidation in eligible multiple myeloma patients
- arrow_rightOptimal transplant timing and conditioning regimen planning
- arrow_rightTandem (double) stem cell transplantation for suitable patients
- arrow_rightPost-transplant monitoring and management of complications
- arrow_rightGraft-versus-host disease research and clinical management
- arrow_rightLong-term follow-up programme for transplant recipients
CAR-T Cell Therapy & Cellular Therapies
Access to Seoul St. Mary's Hospital's CAR-T programme, one of Korea's advanced cellular therapy platforms.
- arrow_rightCAR-T cell therapy for eligible relapsed or refractory blood cancers
- arrow_rightMultidisciplinary evaluation for CAR-T candidacy including prior treatment history and performance status
- arrow_rightMonitoring and management of CAR-T-associated toxicities
Procedures Performed
Clinical services across haematology, transplantation, and cellular therapy
Prof. Min's procedural scope covers the full pathway of myeloma care and haematopoietic transplantation, from initial disease workup and treatment planning through advanced cellular therapies and long-term monitoring.
Haematopoietic Stem Cell Transplantation
TransplantAutologous and allogeneic transplant services for blood cancers including multiple myeloma.
Myeloma Treatment Planning & Systemic Therapy
Medical OncologyPersonalised treatment planning and administration for multiple myeloma across all lines of therapy.
CAR-T Cell & Cellular Therapy
Complex DiseaseAdvanced cellular therapy programme for eligible patients with relapsed or refractory haematological malignancies.
Second Opinion & Case Review
Second OpinionExpert review of myeloma diagnosis, treatment history, and relapse management for patients seeking an independent opinion.
Research & Publications
Peer-reviewed contributions in myeloma, transplantation, and haematology
Prof. Min has an extensive academic record in multiple myeloma, haematopoietic stem cell transplantation, and plasma cell disorders. His research spans treatment outcomes in myeloma, transplant strategy, novel immunotherapy agents, and circulating tumour DNA monitoring.
Prof. Min is an active clinician-researcher in multiple myeloma and transplantation. A more detailed publication list is available on request through Seoul St. Mary's Hospital or the Catholic University of Korea research portal.
Education & Training
Prof. Min completed his medical training and doctoral studies entirely at the Catholic University of Korea, and undertook advanced transplant training at the University of Michigan in 2002.
Clinical Experience
Prof. Min has spent his entire clinical and academic career at Seoul St. Mary's Hospital and the Catholic University of Korea, holding successive leadership roles across haematology, myeloma care, and institutional administration.
Languages & International
Prof. Min consults in Korean. Seoul St. Mary's Hospital's International Healthcare Centre provides multilingual support for international patients.
CancerFax coordinates professional medical interpreter services for international patients, ensuring no language barrier during consultation or case preparation.
CancerFax can coordinate professional medical interpreter support for patients consulting in English or other languages.
How CancerFax Helps You Access Dr. Chang-Ki Min
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Chang-Ki Min's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Chang-Ki Min's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Chang-Ki Min before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Chang-Ki Min's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Chang-Ki Min's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Chang-Ki Min's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Chang-Ki Min
Prof. Chang-Ki Min specialises in haematology, with a primary focus on multiple myeloma, plasma cell disorders, and haematopoietic stem cell transplantation. He is also involved in CAR-T cell therapy and advanced cellular therapies at Seoul St. Mary's Hospital.
Prof. Min is based at Seoul St. Mary's Hospital, The Catholic University of Korea, in Seoul, South Korea. He currently serves as Professor of Hematology and has also been appointed Vice-Chancellor and Medical Director of the Catholic University Medical Center from September 2025.
Seoul St. Mary's Hospital has an International Healthcare Centre with appointment request services and second-opinion pathways. CancerFax can coordinate medical-record review, case preparation, and consultation support for international patients seeking an opinion from Prof. Min, subject to hospital availability and case acceptance.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review your documents, prepare a structured case summary, and coordinate the next steps with Seoul St. Mary's Hospital, subject to availability. The consultation format and timeline depend on the hospital's schedule.
Yes. Prof. Min is closely associated with haematopoietic stem cell transplantation. Seoul St. Mary's Hospital is the first institution in Korea to record 10,000 accumulated haematopoietic stem cell transplants, with Prof. Min performing the landmark 10,000th procedure in December 2022. His transplant work includes autologous stem cell transplantation for multiple myeloma and management of post-transplant complications.
Seoul St. Mary's Hospital's haematology department uses CAR-T cell therapy, bispecific antibody therapy, and other cellular therapies for selected patients with blood cancers including multiple myeloma. Eligibility for CAR-T therapy depends on individual case factors, prior treatment history, and clinical assessment. CancerFax can assist with submitting your records for review.
Connect with Chang-Ki Min Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.